Skip to main content

Early Experiences with Nasal Vaccines against Meningococcal Disease

  • Protocol
  • 798 Accesses

Part of the Methods in Molecular Medicine™ book series (MIMM,volume 66)

Abstract

In common with most infectious agents, meningococci invade mucosal membranes before causing disease (1). An attractive vaccine strategy is therefore to induce immunological responses at the mucosal surfaces, with the possibility of blocking microbial invasion, as well as to induce systemic immunity with the capacity of inactivating the microbes.

Keywords

  • Meningococcal Disease
  • Neisseria Meningitidis
  • Mucosal Vaccine
  • Intranasal Immunization
  • Nasal Drop

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Protocol
USD   49.95
Price excludes VAT (USA)
  • DOI: 10.1385/1-59259-148-5:223
  • Chapter length: 17 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-1-59259-148-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.99
Price excludes VAT (USA)
Hardcover Book
USD   229.00
Price excludes VAT (USA)
Fig. 1.
Fig. 2.

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Griffiss, J. M. (1995) Mechanisms of host immunity, in Meningococcal Disease (Cartwright, K. A. V., ed.), John Wiley and Sons, Chichester, UK, pp. 35–70.

    Google Scholar 

  2. Ala’Aldeen, D. A. A., and Griffiths, E. (1995) Vaccines against meningococcal Disease, in Molecular and Clinical Aspects of Bacterial Vaccine Development (Ala’Aldeen, D. A. A. and Hormaeche, C. E., eds.) John Wiley and Sons, Chichester, UK, pp. 1–39.

    Google Scholar 

  3. Brandtzaeg, P., Farstad, I. N., Johansen, F.-E., Morton, H. C., Norderhagen, I. N., and Yamanaka, T. (1999) The B-cell system of human mucosae and exocrine glands. Immunol. Rev. 171, 45–87.

    CAS  CrossRef  PubMed  Google Scholar 

  4. McGhee, J. R., Mestecky, J., Dertzbaugh, M. T., Eldridge, J. H., Hirasawa, M., and Kiyono, H. (1992) The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10, 75–88.

    CAS  CrossRef  PubMed  Google Scholar 

  5. Walker, R. I. (1994) New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12, 387–400.

    CAS  CrossRef  PubMed  Google Scholar 

  6. Haneberg, B., Dalseg, R., Wedege, E., Høiby, E. A., Haugen, I. L., Oftung, F., et al. (1998) Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66, 1334–1341.

    CAS  PubMed  Google Scholar 

  7. Drabick, J. J., Brandt, B. L., Moran, E. E., Saunders, N. B., Shoemaker, D. R., and Zollinger, W. D. (2000) Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 18, 160–172.

    CrossRef  Google Scholar 

  8. Tang, C., Moxon, R., and Levine, M. M. (1999) For discussion: live attenuated vaccines for group B meningococcus. Vaccine 17, 114–117.

    CAS  CrossRef  PubMed  Google Scholar 

  9. American Academy of Pediatrics, Committee on Infectious Diseases (1999) Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Pediatrics 104, 1404–1406.

    CrossRef  Google Scholar 

  10. Bitnun, A., Shannon, P., Durward. A., Rota, P. A., Bellini, W. J., Graham, C., et al. (1999) Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin. Infect. Dis. 29, 855–861.

    CAS  CrossRef  PubMed  Google Scholar 

  11. Centers for Disease Control and Prevention (1999) Intussuspection among recipients of rotavirus vaccine: United States, 1998–1999. MMWR Morb. Mortal. Wkly. Rep. 48, 577–581.

    Google Scholar 

  12. Talbot, E. A., Perkins, M. D., Silva, S. F. M., and Frothingham, R. (1997) Disseminated Bacille Calmette-Guérin disease after vaccination: case report and review. Clin. Infect. Dis. 24, 1139–1146.

    CAS  CrossRef  PubMed  Google Scholar 

  13. van Loon, F. P. L., Clemens, J. D., Chakraborty, J., Rao, M. R., Kay, B. A., Sack, D. A., et al. (1996) Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years follow-up. Vaccine 14, 162–166.

    CrossRef  PubMed  Google Scholar 

  14. Richman, L. K., Chiller, J. M., Brown, W. R., Hanson, D. G., and Vaz, N. M. (1978) Enterically induced immunologic tolerance. I. Induction of suppressor T lymphocytes by intragastric administration of soluble proteins. J. Immunol. 121, 2429–2434.

    CAS  PubMed  Google Scholar 

  15. Ogra, P. L. (1996) Mucosal immunoprophylaxis: an introductory overview, in Mucosal Vaccines (Kiyono, H., Ogra, P. L., and McGhee, J. R., eds.), Academic Press, San Diego, CA, pp. 3–14.

    CrossRef  Google Scholar 

  16. Levine, M. M. and Dougan, G. (1998) Optimism over vaccines administered via mucosal surfaces. Lancet 351, 1375–1376.

    CAS  CrossRef  PubMed  Google Scholar 

  17. Holmgren, J., Lycke, N., and Czerkinsky, C. (1993) Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11, 1179–1184.

    CAS  CrossRef  PubMed  Google Scholar 

  18. Agren, L., Lowenadler, B., and Lycke, N. (1998) A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell. Biol. 76, 280–287.

    CAS  CrossRef  PubMed  Google Scholar 

  19. Douce, G., Giannelli, V., Pizza, M., Lewis, D., Everest, P., Rappuoli, R., and Dougan, G. (1999) Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 67, 4400–4406.

    CAS  PubMed  Google Scholar 

  20. Sun, J.-B., Rask, C., Olsson, T., Holmgren, J., and Czerkinsky, C. (1996) Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA 93, 7196–7201.

    CAS  CrossRef  PubMed  Google Scholar 

  21. Dalseg, R., Wedege, E., Holst, J., Haugen, I. L., Høiby, E. A., and Haneberg, B. (1999) Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine 17, 2336–2345.

    CAS  CrossRef  PubMed  Google Scholar 

  22. Hvalbye, B. K. R., Aaberge, I. S., Løvik, M., and Haneberg, B. (1999) Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect. Immun. 67, 4320–4325.

    CAS  PubMed  Google Scholar 

  23. Hordnes, K., Tynning, T., Brown, T. A., Haneberg, B., and Jonsson, R. (1997) Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15, 1244–1251.

    CAS  CrossRef  PubMed  Google Scholar 

  24. Berstad, A. K. H., Holst, J., Møgster, B., Haugen, I. L., and Haneberg, B. (1997) A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine 15, 1473–1478.

    CAS  CrossRef  PubMed  Google Scholar 

  25. Oftung, F., Næss, L. M., Wetzler, L. M., Korsvold, G. E., Aase, A., Høiby, E. A., et al. (1999) Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67, 921–927.

    CAS  PubMed  Google Scholar 

  26. Berstad, A. K. H., Holst, J., Frøholm, L. O., Haugen, I. L., Wedege, E., Oftung, F., and Haneberg, B. (2000) A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol. 49, 157–163.

    CAS  PubMed  Google Scholar 

  27. Dalseg, R., Holst, J., Tangen, T., Stabbetorp, G., Simonsen, P., Jantzen, E., et al. (1996) Outer membrane vesicles from group B meningococci can act as mucosal adjuvant for influenza virus antigens, in Vaccine 96; Molecular Approaches to the Control of Infectious Diseases (Brown, E., Norrby, E., Burton, D., and Mekalanos, J., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 177–182.

    Google Scholar 

  28. Berstad, A. K. H., Andersen, S. R., Dalseg, R., Drømtorp, S., Holst, J., Namork, E., et al. (2000) Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine 18, 1910–1919.

    CAS  CrossRef  PubMed  Google Scholar 

  29. Bergquist, C., Johansson, E.-L., Lagergård, T., Holmgren, J., and Rudin A. (1997) Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and vagina. Infect. Immun. 65, 2676–2684.

    CAS  PubMed  Google Scholar 

  30. Del Giudice, G. and Rappuoli, R. (1999) Genetically derived toxoids for use as vaccines and adjuvants. Vaccine 17, S44–S52.

    CrossRef  PubMed  Google Scholar 

  31. Quraishi, M. S., Jones, N. S., and Mason, J. D. T. (1997) The nasal delivery of drugs. Clin. Otolaryngol. 22, 289–301.

    CAS  CrossRef  PubMed  Google Scholar 

  32. Lale, A. M., Mason, J. D. T., and Jones, N. S. (1998) Mucociliary transport and its assessment: a review. Clin. Otolaryngol. 23, 388–396.

    CAS  CrossRef  PubMed  Google Scholar 

  33. Winther, B. and Innes, D.J. (1994) The human adenoid. A morphologic study. Arch. Otolaryngol. Head. Neck. Surg. 120, 144–149.

    CAS  PubMed  Google Scholar 

  34. Anonymous (1997) Nasal preparations. Ph. Eur. 3rd Ed. (Council of Europe, Strasbourgh Cedex) pp. 1763–1765.

    Google Scholar 

  35. Anonymous (1997) Parenteral preparations. Ph. Eur. 3rd Ed. (Council of Europe, Strasbourgh Cedex) pp. 1765–1767.

    Google Scholar 

  36. Holst Fredriksen, J., Rosenqvist, E., Wedege, E., Bryn, K., Bjune, G., Frøholm, L. O., et al. (1991) Production, characterization, and control of Men B-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14, 67–79.

    Google Scholar 

  37. Claassen, I., Meylis, J., van der Ley, P., Peeters, C., Brons, H., Robert, J., et al. (1996) Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14, 1001–1008.

    CAS  CrossRef  PubMed  Google Scholar 

  38. Hammon, S. and Egelberg, P. (1999) Particle size and shape measurement by automated microscopy. Eur. Pharm. Rev. 4, 16–20.

    Google Scholar 

  39. Anger, S., Caldwell, K., Niehus, H., and Müller, R. H. (1999) High resolution size determination of 20 nm colloidal gold particles by SedFFF. Pharm. Res. 16, 1743–1747.

    CAS  CrossRef  PubMed  Google Scholar 

  40. Woodle, M. C., Collins, L. R., Sponsler, E., Kossovsky, N., Papahadjopoulos, D., and Martin, F. J. (1992) Sterically stabilized liposomes. Biophys. J. 61, 902–910.

    CAS  CrossRef  PubMed  Google Scholar 

  41. Haneberg, B., Huynh, P., Nordsaeter, T., Haugen, I. L., Holst, J., and Aaberge, I. S. (1999) Intranasal immunization can generate better antibody responses when the antigen is given repeatedly in small doses. Immunol. Lett. 69, 177.

    Google Scholar 

  42. Bakke, H., Haugen, I. L., Lie, K., Korsvold, G. E., Holst, J., Aaberge, I. S., et al. (1999) A bacterial outer membrane vesicle vaccine given intranasally can induce immunological memory with strong booster responses. Immunol. Lett. 69, 178.

    Google Scholar 

  43. Haneberg, B., Kendall, D., Amerongen, H. M., Apter, F. M., Kraenhbuhl, J.-P., and Neutra, M. R. (1994) Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62, 15–23.

    CAS  PubMed  Google Scholar 

  44. Haneberg, B., Kendall, D., Apter, F. M., and Neutra, M. R. (1997) Distribution of monoclonal antibodies in intestinal and urogenital secretions of mice bearing hybridoma ‘backpack’ tumours. Scand. J. Immunol. 45, 151–159.

    CAS  CrossRef  PubMed  Google Scholar 

  45. Vetvik, H., Grewal, H. M. S., Haugen, I. L., Åhrén, C., and Haneberg, B. (1998) Mucosal antibodies can be measured in air-dried samples of saliva and feces. J. Immunol. Meth. 215, 163–172.

    CAS  CrossRef  Google Scholar 

  46. Berstad, A. K. H., Oftung, F., Korsvold, G. E., Haugen, I. L., Frøholm, L. O., Holst, J., and Haneberg B. (2000) Induction of antigen-specific T cell responses in humans after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 18, 2323–2330.

    CAS  CrossRef  PubMed  Google Scholar 

  47. Perkins, B. A., Jonsdottir, K., Briem, H., Griffiths, E., Plikaytis, B. D., Høiby, E. A., et al. (1998) Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177, 683–691.

    CAS  CrossRef  PubMed  Google Scholar 

  48. Fuglesang, J.E., Høiby, E. A., Holst, J., Rosenqvist, E., and Nøkleby H. (1998) Increased and longer-lasting immune responses to the Norwegian meningococcal group B OMV vaccine in teenagers with a three-dose compared to a two-dose regimen, in Eleventh International Pathogenic Neisseria Conference (Nassif, X., Quentin-Millet, M.-J., and Taha, M.-K., eds.), Editions EDK, Paris, France, p. 174.

    Google Scholar 

  49. Bergquist, C., Lagergård, T., and Holmgren, J. (1997) Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect. Immun. 65, 1579–1583.

    CAS  PubMed  Google Scholar 

  50. Wedege, E., Bryn, K., and Frøholm, L. O. (1998) Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J. Immunol. Methods 113, 51–59.

    CrossRef  Google Scholar 

  51. Høiby, E. A., Rosenqvist, E., Frøholm, L. O., Bjune, G., Feiring, B., Nøkleby, H., and Rønnild, E. (1991) Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14, 147–156.

    PubMed  Google Scholar 

  52. Bjune, G., Høiby, E. A., Grønnesby, J. K., Arnesen, O., Holst Fredriksen, J., Halstensen, A., et al. (1991) Effect of an outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. Lancet 338, 1093–1096.

    CAS  CrossRef  PubMed  Google Scholar 

  53. Saunders, N. B., Shoemaker, D. R., Moran, E. E., Larsen, T., and Zollinger, W. D. (1999) Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect. Immun. 67, 113–119.

    CAS  PubMed  Google Scholar 

  54. Simecka, J. W., Jackson, R. J., Kiyono, H., and McGhee, J. R. (2000) Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract. Infect. Immun. 68, 672–679.

    CAS  CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2001 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Holst, J., Haneberg, B. (2001). Early Experiences with Nasal Vaccines against Meningococcal Disease. In: Pollard, A.J., Maiden, M.C. (eds) Meningococcal Vaccines. Methods in Molecular Medicine™, vol 66. Humana Press. https://doi.org/10.1385/1-59259-148-5:223

Download citation

  • DOI: https://doi.org/10.1385/1-59259-148-5:223

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-801-1

  • Online ISBN: 978-1-59259-148-0

  • eBook Packages: Springer Protocols